Solid‐Phase Synthesis and Biological Evaluation of Peptides ADP‐Ribosylated at Histidine

Author:

Minnee Hugo1,Rack Johannes G. M.23,van der Marel Gijsbert A.1,Overkleeft Herman S.1,Codée Jeroen D. C.1,Ahel Ivan2,Filippov Dmitri V.1ORCID

Affiliation:

1. Bio-Organic Synthesis Leiden Institute of Chemistry Leiden University RA-2300 Leiden The Netherlands

2. Sir William Dunn School of Pathology University of Oxford South Parks Road Oxford OX1 3RE UK

3. Current address: Medical Research Council Centre for Medical Mycology at the University of Exeter University of Exeter, Geoffrey Pope Building Stocker Road Exeter EX4 4QD UK

Abstract

AbstractThe transfer of an adenosine diphosphate (ADP) ribose moiety to a nucleophilic side chain by consumption of nicotinamide adenine dinucleotide is referred to as ADP‐ribosylation, which allows for the spatiotemporal regulation of vital processes such as apoptosis and DNA repair. Recent mass‐spectrometry based analyses of the “ADP‐ribosylome” have identified histidine as ADP‐ribose acceptor site. In order to study this modification, a fully synthetic strategy towards α‐configured N(τ)‐ and N(π)‐ADP‐ribosylated histidine‐containing peptides has been developed. Ribofuranosylated histidine building blocks were obtained via Mukaiyama‐type glycosylation and the building blocks were integrated into an ADP‐ribosylome derived peptide sequence using fluorenylmethyloxycarbonyl (Fmoc)‐based solid‐phase peptide synthesis. On‐resin installation of the ADP moiety was achieved using phosphoramidite chemistry, and global deprotection provided the desired ADP‐ribosylated oligopeptides. The stability under various chemical conditions and resistance against (ADP‐ribosyl) hydrolase‐mediated degradation has been investigated to reveal that the constructs are stable under various chemical conditions and non‐degradable by any of the known ADP‐ribosylhydrolases.

Funder

Medical Research Council Centre for Medical Mycology

Medical Research Council

Wellcome Trust

Biotechnology and Biological Sciences Research Council

Cancer Research UK Therapeutic Discovery Laboratories

Ovarian Cancer Research Alliance

Publisher

Wiley

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3